Lv4
460 积分 2022-10-20 加入
Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials
28天前
已关闭
Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation
1个月前
已完结
RAF inhibitors that evade paradoxical MAPK pathway activation
1个月前
已完结
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
3个月前
已完结
Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS ‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan
3个月前
已完结
Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor
3个月前
已完结
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma
5个月前
已完结
Putative allosteric MEK1 and MEK2 inhibitors
11个月前
已完结
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
1年前
已完结
Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials
1年前
已完结
皖公网安备34019202002308
